Wnsfeild Pharmaceuticals
Pharmaceutical company · 119 brands · 122 molecules
Ranked #10 of 106 companies in Antidepressants
Company overview
Wnsfeild Pharmaceuticals is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 119 product registrations across 122 distinct molecules. It is the 139th largest registrant in Pakistan by product count, and ranks 10th of 106 in Antidepressants. Its portfolio is concentrated in Antidepressants and Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.
Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.
Products by Wnsfeild
9 products matched in our catalogue — each with its observed price and DRAP approved ceiling.
Price ceiling age
DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.
Top molecules by brand count
Therapeutic classes
Conditions treated
Price band (DRAP official ceilings)
Regulatory record
No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.
Competitive set
Companies whose registered portfolio overlaps most with this one.
Portfolio whitespace
Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.
Get the full profile for Wnsfeild
This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.
Request this brief See what’s included